• eLichens

  Participated · Equity · Jul 2016

  eLichens develops patented micro gas sensors and a comprehensive AI-based platform for indoor and outdoor air quality analysis and prediction. Its product set includes sensor hardware and integrated stations aimed at smart city, smart home and smart building markets. The company plans to market large volumes of its micro gas sensors to industrial customers and deploy its platform at scale for urban gas leak detection, worker safety and energy-efficiency applications. Recent contracts with major international industrial groups have supported commercial traction and international expansion. Financially, eLichens completed a new EUR 7 million capital increase backed by historical investors and new entrants, following an earlier >EUR 4 million raise in July 2016. The team leverages patented technologies developed with partners such as CEA-Leti and MIT and maintains headquarters in Grenoble with offices in California. eLichens develops software and miniaturized optical micro-sensors to digitalize air quality and deliver hyper-local, personalized air-quality information. Its innovative, patented solutions are developed jointly with research laboratories including CEA-Leti and target industrial, smart home, smart city and consumer electronics applications. The company emphasizes ultra-low power consumption sensors and a broad patent portfolio as technological differentiators. eLichens plans to accelerate time to market for smart sensor products and deploy solutions for gas/pollutants detection, analysis and prediction in consumer and industrial markets. The recently announced strategic fundraising of over €3 million will be used to deliver products to first customers, recruit talent and step up investment in innovation to complement its technology portfolio. Management says the team has established strategic industrial partnerships, has a presence in the US, Europe and Asia, and aims to become a leader in air quality services.

• Ixaltis

  Participated · Equity · May 2016

  Ixaltis is a Toulouse-based biopharmaceutical research and clinical development company focused on genito-urinary diseases. The company acquired three molecules including litoxetine (IXA-001) under exclusive licence from Sanofi, IXA-002 (an MAO A-B inhibitor) and IXA-003 (an MAO B inhibitor). Litoxetine has shown efficacy in preclinical trials and Ixaltis has started proof-of-concept/Phase 2 studies in urinary incontinence. The company says it will use the newly raised funds to continue research into urinary incontinence. Ixaltis raised €8m in its first funding round from a group of investors and was also granted a €2.8m OSEO loan for the MAGENTA collaborative industrial research project. The company was created by urology and pharmaceutical experts Dr Philippe Lluel, Christian Chavy, Dr Roberto Gradnik and Professors Pascal Rischmann and Xavier Gamé.

• FineHeart

  Participated · Series A · Mar 2016

  FineHeart is a clinical-stage medical device company headquartered in Bordeaux and Tours that is building FlowMaker®, the first fully implantable cardiac output accelerator designed for advanced heart failure. The intraventricular pump synchronizes with native heart contractions, preserves physiological blood flow, and is wirelessly recharged via transcutaneous energy transfer, sharply lowering infection risk. Implantation is performed on a beating heart through a minimally invasive 90-minute procedure, giving surgeons a familiar workflow. The technology addresses a market of about 200,000 patients a year and initially targets the 50,000 most severe cases not served by current LVADs, an opportunity valued at more than €5 billion. FineHeart protects its platform with 160 patents across 27 families. With the latest funding, the company plans to industrialize FlowMaker® hardware, run clinical trials, and solidify its leadership in active implantable medical devices (AIMDs).

• Biom'Up

  Participated · Series C · Sep 2015

  Biom'Up develops a new generation hemostatic product, HEMOBLAST TM, and markets proprietary collagen-based products including COVA TM, COVAMESH TM and MATRITM BONE. The company focuses on absorbable medical devices for use in biosurgery. Management is led by CEO Étienne Binant. Biom'Up reported turnover of more than €3m in 2014 and expected over 30% sales growth for its existing product portfolio in 2015. The company plans to use new funds to further develop HEMOBLAST TM, specifically to support its clinical study activities in Europe and North America. Operations are based in Saint-Priest, France. Biom'Up designs, develops and manufactures re-absorbable medical implants for a range of surgical applications from nerve regeneration to cardio-thoracic surgery. Its marketed products include COVA, a membrane for prevention of adhesions and controlled healing available in Europe and the US, and MATRI BONE, a bone regeneration matrix sold in Europe. The company employs 27 people, including eight engineers and three doctors. Biom'Up plans to use new funding to strengthen its sales team to accelerate domestic and export roll-out and to finance a phase III clinical trial in Europe and the US for a new product range targeting major surgery and regenerative medicine markets. It has initiated a US development strategy by filing initial 510(k) applications with the FDA and establishing a multidisciplinary scientific advisory board of opinion leaders in France and the US. Founded in 2005 and based in Lyon, France, Biom'Up is focused on advancing its clinical pipeline and commercial expansion.

No current team members are available.